Ignite Creation Date:
2024-05-06 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 12:43 PM
Study NCT ID:
NCT03495479
Status:
WITHDRAWN
Last Update Posted:
2021-10-18
First Post:
2016-06-14
Brief Title:
Aneustat Treatment of Localized Prostate Cancer Under Active Surveillance
Sponsor:
Omnitura Therapeutics Inc
Organization:
Omnitura Therapeutics Inc
Study Overview
Official Title:
Phase IIA Single-Center Single-Arm Clinical Study of OMN54 Aneustat in Men Diagnosed With Prostate Cancer Being Followed by Active Surveillance
Status:
WITHDRAWN
Status Verified Date:
2021-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
No funding
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CAMPAS
Brief Summary:
Assessment of the effects of OMN54 Aneustat in a population of men with indolent prostate cancer who are otherwise healthy and free of significant co-morbidities and have chosen active surveillance for disease management The investigators will assess how OMN54 affects PSA overall tumor burden in addition to any changes in urinary flow Other biomarkers will be tested to follow disease evolution
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None